198 related articles for article (PubMed ID: 33095334)
1. [Anakinra therapy in a patient with multifocal pyoderma gangrenosum and hidradenitis suppurativa].
Oymanns M; Kreuter A; Assaf C
Hautarzt; 2021 May; 72(5):435-438. PubMed ID: 33095334
[TBL] [Abstract][Full Text] [Related]
2. Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne.
Vinkel C; Thomsen SF
Int J Dermatol; 2017 Aug; 56(8):811-818. PubMed ID: 28345207
[TBL] [Abstract][Full Text] [Related]
3. Pyoderma gangrenosum associated with cystic acne and hidradenitis suppurativa controlled by adding minocycline and sulfasalazine to the treatment regimen.
Shenefelt PD
Cutis; 1996 May; 57(5):315-9. PubMed ID: 8726710
[TBL] [Abstract][Full Text] [Related]
4. Treatment of pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) with weight-based anakinra dosing in a Hepatitis B carrier.
Jennings L; Molloy O; Quinlan C; Kelly G; O'Kane M
Int J Dermatol; 2017 Jun; 56(6):e128-e129. PubMed ID: 28239847
[No Abstract] [Full Text] [Related]
5. [Pyoderma gangrenosum associated with hidradenitis suppurativa: a case report and review of the literature].
García-Rabasco AE; Esteve-Martínez A; Zaragoza-Ninet V; Sánchez-Carazo JL; Alegre-de-Miquel V
Actas Dermosifiliogr; 2010 Oct; 101(8):717-21. PubMed ID: 20965015
[TBL] [Abstract][Full Text] [Related]
6. Pyoderma gangrenosum, acne, psoriasis, arthritis and suppurative hidradenitis (PAPASH)-syndrome: a new entity within the spectrum of autoinflammatory syndromes?
Garzorz N; Papanagiotou V; Atenhan A; Andres C; Eyerich S; Eyerich K; Ring J; Brockow K
J Eur Acad Dermatol Venereol; 2016 Jan; 30(1):141-3. PubMed ID: 25070077
[No Abstract] [Full Text] [Related]
7. Spectrum of diseases associated with pyoderma gangrenosum and correlation with effectiveness of therapy: New insights on the diagnosis and therapy of comorbid hidradenitis suppurativa.
Fischer AH; Jourabchi N; Khalifian S; Lazarus GS
Wound Repair Regen; 2022 May; 30(3):338-344. PubMed ID: 35385180
[TBL] [Abstract][Full Text] [Related]
8. Remission of refractory pyoderma gangrenosum, severe acne, and hidradenitis suppurativa (PASH) syndrome using targeted antibiotic therapy in 4 patients.
Join-Lambert O; Duchatelet S; Delage M; Miskinyte S; Coignard H; Lemarchand N; Alemy-Carreau M; Lortholary O; Nassif X; Hovnanian A; Nassif A
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S66-9. PubMed ID: 26470620
[TBL] [Abstract][Full Text] [Related]
9. Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated With infliximab.
Groleau PF; Grossberg AL; Gaspari AA
Cutis; 2015 Jun; 95(6):337-42. PubMed ID: 26125210
[TBL] [Abstract][Full Text] [Related]
10. PASS Syndrome: An IL-1-Driven Autoinflammatory Disease.
Leuenberger M; Berner J; Di Lucca J; Fischer L; Kaparos N; Conrad C; Hohl D; So A; Gilliet M
Dermatology; 2016; 232(2):254-8. PubMed ID: 26919742
[TBL] [Abstract][Full Text] [Related]
11. Non-response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa.
Sun NZ; Ro T; Jolly P; Sayed CJ
J Clin Aesthet Dermatol; 2017 Sep; 10(9):36-38. PubMed ID: 29344326
[TBL] [Abstract][Full Text] [Related]
12. Pyoderma gangrenosum, acne conglobata, suppurative hidradenitis, and axial spondyloarthritis: efficacy of anti-tumor necrosis factor α therapy.
Bruzzese V
J Clin Rheumatol; 2012 Dec; 18(8):413-5. PubMed ID: 23188209
[TBL] [Abstract][Full Text] [Related]
13. Pyoderma gangrenosum and concomitant hidradenitis suppurativa--rapid response to canakinumab (anti-IL-1β).
Jaeger T; Andres C; Grosber M; Zirbs M; Hein R; Ring J; Traidl-Hoffmann C
Eur J Dermatol; 2013; 23(3):408-10. PubMed ID: 23816498
[No Abstract] [Full Text] [Related]
14. Novel PSTPIP1 gene mutation in pyoderma gangrenosum, acne and suppurative hidradenitis syndrome.
Saito N; Minami-Hori M; Nagahata H; Nozaki H; Iinuma S; Igawa S; Kanno K; Kishibe M; Kanazawa N; Ishida-Yamamoto A
J Dermatol; 2018 Aug; 45(8):e213-e214. PubMed ID: 29575118
[No Abstract] [Full Text] [Related]
15. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome.
Braun-Falco M; Kovnerystyy O; Lohse P; Ruzicka T
J Am Acad Dermatol; 2012 Mar; 66(3):409-15. PubMed ID: 21745697
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporin-responsive hidradenitis suppurativa.
Buckley DA; Rogers S
J R Soc Med; 1995 May; 88(5):289P-290P. PubMed ID: 7636825
[TBL] [Abstract][Full Text] [Related]
17. Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa Syndrome: A Case Report and Literature Review.
Huang J; Tsang LS; Shi W; Li J
Front Med (Lausanne); 2022; 9():856786. PubMed ID: 35402426
[TBL] [Abstract][Full Text] [Related]
18. Pyoderma gangrenosum, acne, hidradenitis suppurativa syndrome associated with type 1 diabetes mellitus treated with adalimumab.
Fattore D; Pistone G; Bongiorno MR
G Ital Dermatol Venereol; 2019 Apr; 154(2):218-220. PubMed ID: 29368847
[No Abstract] [Full Text] [Related]
19. [Autoinflammatory skin diseases : Diagnosis and therapy].
Ehrchen J; Drerup C
Hautarzt; 2020 May; 71(5):359-364. PubMed ID: 32253451
[TBL] [Abstract][Full Text] [Related]
20. Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: A retrospective chart review.
Wang LL; Micheletti RG
J Am Acad Dermatol; 2020 Feb; 82(2):507-510. PubMed ID: 31541746
[No Abstract] [Full Text] [Related]
[Next] [New Search]
